(RTTNews) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (MSHL) said it appointed Thomas Zech as the company's Chief Financial Officer and Company Secretary based in San Diego. This follows the appointment of Daniel Gold as Chief Executive Officer of the North Ryde, Australia-based pharmaceutical company Marshall Edwards, Inc. in April 2010.
Following the appointments, Novogen has restructured its Australian management team and has appointed Mark Hinze as Chief Financial Officer and Operations Manager of Novogen. Hinze has been with the Novogen Group for over 10 years and previously held the position of the Group's Financial Controller.
David Seaton, who was previously Chief Financial Officer of Novogen and Chief Financial Officer and Company Secretary of Marshall Edwards, Inc., and more recently Acting Chief Executive Officer, would leave the company immediately. Also, due to the high priority of current and future clinical programs now being managed from the US, Novogen's Group Director of Research Professor Alan Husband would leave the Group at the end of June 2010.
MSHL closed Thursday's regular trading session at $1.46, on a volume of 11 thousand shares on the Nasdaq.